Phentolamine Mesylate Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 5 mg/mL
Reference Brands: Regitine (USA)
Category:
Heart Disorder
Phentolamine Mesylate is available in Injection
and strengths such as 5 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Phentolamine Mesylate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Phentolamine Mesylate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Phentolamine mesylate is the mesylate salt of a synthetic imidazoline compound with potent alpha-adrenergic antagonist activity. It acts as a competitive, non-selective blocker of both alpha-1 and alpha-2 adrenergic receptors, leading to peripheral vasodilatation and a reduction in peripheral vascular resistance. Through this mechanism, phentolamine produces a rapid decrease in blood pressure. In addition to its alpha-adrenergic effects, phentolamine may also block 5-hydroxytryptamine (5-HT) receptors and stimulate the release of histamine from mast cells, contributing further to its vasodilatory action.
The primary clinical application of phentolamine is in the management of hypertensive emergencies, particularly those associated with pheochromocytoma, where excessive catecholamine release causes severe and potentially life-threatening hypertension. Its rapid onset of action makes it especially useful in acute care and hospital settings.
Phentolamine also has a role in the management of cocaine-induced cardiovascular complications. In such cases, beta-blockers are generally avoided due to the risk of unopposed alpha-adrenergic stimulation, which can worsen coronary vasoconstriction, myocardial ischemia, and hypertension. Phentolamine is not considered a first-line treatment for this indication and is reserved for patients who do not adequately respond to standard therapies such as benzodiazepines, nitroglycerin, and calcium channel blockers.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing